Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

3.29

Mkt cap

11M

Volume

136K

High

3.57

P/E Ratio

-0.01

52-wk high

152.40

Low

3.29

Div yield

N/A

52-wk low

1.80

U.S. stocks showed mixed performance with the Dow Jones falling by 150 points and the NASDAQ rising by 0.56%. The U.S. economy added 353,000 jobs in January, surpassing expectations. Intelligent Bio Solutions Inc. (INBS), Minim, Inc. (MINM), and Remark Holdings, Inc. (MARK) saw significant stock price increases, while Cingulate Inc. (CING), MedAvail Holdings, Inc. (MDVL), and GRI Bio, Inc. (GRI) experienced notable declines.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 2:48 pm

Cingulate has announced the pricing of its public offering, aiming to raise $7.5 million through the sale of 3.750 million shares at a price of $2.00 per share.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:23 pm

Meta Platforms, Inc. (META) shares surged over 16% in pre-market trading due to strong fourth-quarter results and a new quarterly dividend. Other stocks also showed significant pre-market movements, with notable gainers including CCSC Technology International Holdings Limited (CCTG) and The Clorox Company (CLX), and losers like AgriFORCE Growing Systems Ltd. (AGRI) and Skechers U.S.A., Inc. (SKX).

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 1:21 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. MyMD Pharmaceuticals, PaxMedica, Oragenics, Lineage Cell Therapeutics, BioRestorative Therapies, and Codexis experienced gains, with increases ranging from 5.81% to 9.3%. Conversely, Kiora Pharmaceuticals, Cingulate, Adagene, Sharps Technology, Alzamend Neuro, and Redhill Biopharma saw declines between 6.48% and 10.6%. These movements reflect significant volatility within the healthcare sector, impacting the market value of these companies.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:31 pm

Cingulate has appointed Jennifer Callahan as its new CFO, replacing Lou Van Horn. This change in the company's financial leadership could signal a strategic shift or a strengthening of its financial management.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:12 pm

Cingulate has announced that Werth Family Investment Associates has converted $3.3 million of debt and accrued interest into equity at a conversion price of $4.785 per share. This conversion could indicate confidence in Cingulate's future prospects and may affect the company's financial structure and shareholder equity.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:56 am

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Acutus Medical (AFIB) saw a substantial increase of 49.2%, while Kazia Therapeutics (KZIA) and Sunshine Biopharma (SBFM) also posted notable gains. On the downside, SINTX Techs (SINT) and GlycoMimetics (GLYC) experienced declines, along with other stocks such as Cingulate (CING) and Tharimmune (THAR). These movements reflect changes in investor sentiment and can impact the short-term performance of these stocks.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 9:31 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Kura Oncology (KURA) led the gainers with a 48.1% rise, while Annovis Bio (ANVS) saw the largest drop among the losers, falling 19.2%. Other notable movers included Telesis Bio (TBIO), Ensysce Biosciences (ENSC), and Inhibikase Therapeutics (IKT) with substantial gains, and Sight Sciences (SGHT), Gyre Therapeutics (GYRE), and Curis (CRIS) with notable losses.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 5:31 pm

HC Wainwright & Co. has reaffirmed its Buy rating on Cingulate Inc (NASDAQ:CING) and increased its price target from $3.50 to $8.00. Cingulate's shares are currently trading at $7.15, down 0.56% over the last 24 hours. The new price target suggests a potential upside of 11.89%. Cingulate is a clinical stage biopharmaceutical company focused on developing pharmaceutical products with its proprietary drug delivery platform.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 5:00 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on Cingulate (NASDAQ:CING) and increased the price target from $3.5 to $8, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:44 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.